Identification of infants with increased type 1 diabetes (T1D) risk for enrollment into Primary Oral Insulin Trial POInT

This abstract has open access
Abstract Summary

Background: Primary prevention of type 1 diabetes (T1D) requires early intervention in genetically at-risk infants. Neonates and infants who are at increased risk to develop type 1 diabetes can be identified using genetic markers. The Global Platform for the Prevention of Autoimmune Diabetes (GPPAD) has established a screening program, GPPAD-02, that identifies infants who have a high risk of T1D, enroll these children into the primary oral insulin trial (POInT), and follow and monitor them for islet autoantibodies and diabetes.

Methods: Genetic testing is offered either at delivery, together with the regular newborn testing, or at a pediatric baby-visit before the age of 4 months in regions of Germany, UK, Poland, Belgium and Sweden. Using a genetic score based on 46 T1D susceptibility SNPs and the first degree-family history for T1D, infants with a high (>10%) genetic risk for multiple beta-cell autoantibodies by the age of 6 years are identified.

Results: Since October 2017, 11,465 infants participated in the screening, including 247 (2.15%) with a first-degree family history of T1D (FDR). The T1D associated HLA risk genotypes DR3/DR4-DQ8 and DR4-DQ8/DR4-DQ8 were present, respectively, in 224 (2.0%) and 95 (0.85%) children from the general population (GP), and in 13 (5.3%) and 5 (2%) FDR children. In total, 166 (1.45%) infants had a high genetic risk (>10%) and are eligible for enrollment into POInT including 96 (0.86%) GP and 70 (28.3%) FDR children. The median genetic risk score in eligible infants was 14.56 as compared to 10.08 in the non-eligible children.

In conclusion, the first results of the GPPAD-02 study showed that screening for genetic risk in newborns on a population-based level is feasible.

 

 

Submission ID :
IDS7996
Submission Type
Abstract Topics
Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany
Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany
Institute of Diabetes Research, Helmholtz Zentrum München-German Research Center for Environmental Health, Munich (Germany)
Institute of Diabetes Research, Helmholtz Zentrum München, German Research Center for Environmental Health, Munich-Neuherberg, Germany
Katholieke Universiteit Leuven, Leuven (Belgium)
Lund University, Lund (Sweden)
Oxford University, Department of Paediatrics Clinical Vaccine Research and Immunisation Education, Oxford (UK)
Institute of Mother and Child, Warsaw (Poland)
Hannoversche Kinderheilanstalt, Kinder- und Jugendkrankenhaus AUF DER BULT, Hannover (Germany)
DFG Research Center for Regenerative Therapies Dresden (CRTD)-Technische Universität Dresden, Dresden (Germany)
CRTD Center for Regenerative Therapies Dresden

Abstracts With Same Type

Submission ID
Submission Title
Submission Topic
Submission Type
Primary Author
2 visits

KEY DATES

Event dates:
Thursday 25 October - Monday 29 October 2018

Abstract submission deadline:
Monday 14 May 2018

Abstract notification:
July 2018

Early registration deadline:
Monday 3 September 2018

Registration deadline:
Monday 15 October 2018

Contact
British Society for Immunology
+44 (0)20 3019 5901
congress@immunology.org